NASDAQ · DNTH
Dianthus Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DNTH: Nov 4, 2026
Dianthus Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-1. The reported EPS for the same quarter last year was $-0.97.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.00 | $-0.93 | $-1.12 | 7 |
| Dec 2026 | $-1.06 | $-0.97 | $-1.20 | 7 |
| Mar 2027 | $-1.08 | $-0.99 | $-1.26 | 5 |
| Jun 2027 | $-1.14 | $-1.01 | $-1.39 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest · Fintel · RTTNews- Zacks · Oct 29, 9:00 AM EDTHalozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthHalozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- BNK Invest · Oct 22, 4:35 PM EDTDianthus Therapeutics Enters Oversold Territory (DNTH)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- Fintel · Sep 5, 4:47 AM EDTCitigroup Initiates Coverage of Dianthus Therapeutics with Buy RatingFintel reports that on September 4, 2026, Citigroup initiated coverage of Dianthus Therapeutics (NASDAQCM:DNTH) with a Buy recommendation. Dianthus Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing primarily on developing innovat
- RTTNews · Sep 3, 6:55 AM EDTDianthus Therapeutics Grants Inducement Awards To Four New Employees(RTTNews) – Dianthus Therapeutics, Inc. (DNTH), a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases, announced that it granted equity awards to four newly hired, non-executive employees.
- Zacks · Aug 4, 5:40 PM EDTDianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue EstimatesDianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jun 17, 10:29 AM EDTDNTH Shares Surge 89% Over the Past Six Months: What's Driving It?Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
- Barchart · Jun 11, 2:15 PM EDTStocks Settle Sharply Lower on Escalating Middle East TensionsThe S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June E-mini S&P futures (ESM26 ) fell -1.62%, and June E-mini Nasdaq futures…
- Barchart · Jun 10, 7:39 PM EDTStocks Fall on Weakness in Tech and Trucking CompaniesThe S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.28%. June E-mini S&P futures (ESM26 ) are down -0.25%, and June E-mini Nasdaq futures…
- Barchart · Jun 10, 7:02 PM EDTStocks Resume Decline as Chipmakers and AI Companies FallThe S&P 500 Index ($SPX ) (SPY ) today is down -0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures (ESM26 ) are down -0.71%, and June E-mini Nasdaq futures…
- The Motley Fool · May 18, 1:33 PM EDTDianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems BullishOctagon Capital Advisors sold 470,000 shares of Dianthus Therapeutics in the first quarter; the estimated transaction value was $27.22 million (based on quarterly average prices).
- The Motley Fool · May 17, 2:25 PM EDTWhy This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock RallyCormorant acquired 950,000 Dianthus Therapeutics shares in the first quarter, estimated at $55.01 million based on quarterly average prices.
- Zacks · May 5, 5:15 PM EDTDianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue EstimatesDianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Dianthus Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.